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Background Aortic stenosis is a common finding in cardiac amyloidosis (CA). Younger patients often remain asymptomatic. If
unrecognized, this can lead to serious complications such as heart failure. Progression of aortic stenosis can be
accelerated in patients with chronic kidney disease and need for dialysis. Perioperative risk in these patients is often
high due to the underlying systemic disease.
...................................................................................................................................................................................................
Case summary A 40-year-old Caucasian man with known AA amyloidosis, highly active Ankylosing Spondylitis and need for chron-
ic dialysis due to end-stage chronic renal failure presented for echocardiographic routine exam without reporting
any cardiac symptoms. At the last visit 4 years ago, a normal heart valve function was noted and no echocardio-
graphic follow-up was performed in the following. Now, rapid progression with severe aortic valve and mitral valve
stenosis was stated and the patient underwent combined aortic and mitral surgical valve replacement following
discussion in the multidisciplinary cardiology meeting. Macroscopic examination of the valves revealed significant
calcification and histological examination showed the high presence of amyloid by Congo-red staining and immuno-
histological staining for AA-Amyloid. Both valve prosthetic devices showed normal function as well as a normal left
ventricular ejection fraction in initial post-operative transoesophageal echocardiography. After prolonged and com-
plicated post-operative course in the intensive care unit the patient died 3 months after surgery due to intractable
multiorgan failure in combined severe abdominal septic and cardiogenic shock.
...................................................................................................................................................................................................
Discussion Concomitant CA and chronic dialysis can accelerate the onset of severe aortic valve stenosis. Young patients, as in
this case, often stay asymptomatic, perioperative risk increases with duration of chronic dialysis and severity of
valve stenosis. This increases the need for regular short-term echocardiographic examinations even in clinical stable
patients.
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Learning points
• Concomitant cardiac amyloidosis and dialysis can accelerate the onset of severe aortic valve stenosis.
• Regular frequent echocardiographic follow-up, even in clinically stable patients, is important.
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Cardiac amyloidosis (CA) is a rare cause of myocardial thickening
predominantly caused by abnormal deposition of myocardial light
chain or transthyretin amyloid.1 A scarcer cause of CA is systemic
AA amyloidosis, in which the deposited protein is serum amyloid A
protein, an acute-phase protein which is normally soluble and whose
plasma concentration is highest during inflammation. The most
frequent underlying disorder is inflammatory arthritis. The predomin-
ant disease manifestation of AA amyloidosis at diagnosis is renal
dysfunction.2
Diagnosis of cardiac involvement in systemic amyloidosis can be
challenging. Echocardiographic signs of cardiac involvement are left
ventricular wall thickening (left ventricular hypertrophy, LVH), pre-
served apical longitudinal contraction and basal hypokinesia (‘apical
sparing’), and an elevated apical-to-basal gradient (‘cherry on the
cake’) of longitudinal strain.3–5 Additional diagnostic modalities such
as late gadolinium magnetic resonance imaging or transcatheter car-
diac biopsy are recommended by the current guidelines6 if uncertain-
ties on the underlying diagnosis following echocardiography remain.
Aortic stenosis (AS) and other valve disorders secondary to amyl-
oid deposition are common findings in systemic amyloidosis as well
as in chronic dialysis patients, often requiring valve surgery.7,8
Recently, Galat et al.9 published a clinical description of 16 patients
with concomitant aortic stenosis and CA, however, this relates to
mainly older patients with transthyretin CA.
Since patients with systemic amyloidosis often have a high peri-
operative risk due to multiorgan involvement of the underlying dis-
ease, prognosis after valve surgery in these patients is poor.
We report a case of a 40-year-old Caucasian man with rapid pro-
gression of aortic and mitral valve stenosis secondary to AA amyloid-
osis and multiple complications after cardiac surgery.
Timeline
Case presentation
A 40-year-old Caucasian man presented to our cardiologic out-
patient department for regular cardiac evaluation. Dyspnoea or other
cardiologic symptoms were negated by the patient. AA amyloidosis
and associated end-stage chronic renal failure with need for constant
dialysis due to highly active Ankylosing spondylitis was diagnosed
7 years ago and confirmed on kidney biopsy. At initial echocardio-
graphic examination 4 years ago typical left ventricular wall thickening
(19 mm) and ‘apical sparing’ with abnormal longitudinal function was
stated, suspicion of CA was raised. Left ventricular ejection fraction
(LVEF) was normal (60%). Yet, no aortic or mitral dysfunction was
stated. No additional cardiac diagnostic modalities were done be-
cause of potential contrast agent side effects in absence of expected
further therapeutic consequences. The patient continued his regular
visits at the nephrology department. Due to arterial hypertension
and LVH, regular antihypertensive and heart insufficiency medication
was initiated (ramipril 5 mg b.i.d.; lercanidipine 10 mg b.i.d.). Anti-
inflammatory therapy for ankylosing spondylitis consisted of 15 mg
Prednisolone daily. Despite our recommendations no echocardio-
graphic follow-up was performed in the following 4 years till the pre-
sent visit.
In the present echo exam, the patient showed no change in LVH
or LVEF. Surprisingly, while any cardiac symptoms were negated, the
patient now showed severe aortic valve stenosis and mitral valve
stenosis, the valves showing signs of massive calcification (see Figures
1–4, Supplementary material online, Video S1) (left ventricular end-
diastolic volume: 51 mm, left ventricular end-systolic volume: 36 mm,
no pericardial/pleural effusion, no left ventricular outflow tract ob-
struction, no systolic anterior movement, aortic valve mean pressure
gradient: 30.56 mmHg, aortic valve Vmax: 3.8 m/s, aortic valve area:
1.1cm2, mitral valve mean pressure gradient: 13.92 mmHg, mitral
valve area: 1.7cm2, no relevant aortic, mitral, or tricuspid valve regur-
gitation). N-terminal prohormone of brain natriuretic peptide was
>70 000 ng/dL. Electrocardiogram showed regular sinus rhythm,
without any conduction abnormalities. Clinical examination of the pa-
tient showed normal blood pressure (128/68 mmHg), normal heart
rate (58 b.p.m.), rhythmic pulse and normal SpO2 (98%) by pulse ox-
imetry. Auscultation revealed a 3/6 systolic, crescendo-decrescendo
murmur, heard loudest at the 2nd right intercostal space. No periph-
eral oedema or increased jugular vein pulse was present. No hepatic
or splenomegaly was present. Physical examination showed over-
heated and swollen knee joints. Due to suspicion of progressive sys-
temic amyloidosis and ankylosing spondylitis a therapy with
interleukin-6-receptor monoclonal human antibody (Tocilizumab)
was initiated.
Following discussion in the multidisciplinary cardiology meeting,
the decision for surgical valve replacement of the aortic and mitral
valve, due to fast progression, was made. A coronary angiography for
preoperative evaluation showed no relevant coronary stenosis.
Despite the high surgical risk in this patient, transcatheter aortic valve
implantation was rejected by the Heart Team due to the young age
and accompanying severe surgically treatable mitral valve disease in
compliance with the current European Society of Cardiology (ESC)
guidelines for the management of valvular heart disease.6
Surgical replacement of the aortic and mitral valve was conducted
8 weeks after severe aortic valve stenosis and mitral valve stenosis
was diagnosed [23 mm Trifecta GT Aortic Valve (St. Jude Medical
Abbott, St. Paul, MN, USA)/mitral valve prosthesis: 29 mm Hancock II
(Medtronic, Dublin, Ireland)]. Macroscopic examination of the valves
revealed significant calcification and were sent to our pathologic de-
partment for further examination. Both valve prosthetic devices
2014 First echocardiographic signs of cardiac involvement
with left ventricular hypertrophy and typical apical
sparing. No valve dysfunction, preserved left ven-
tricular ejection fraction (LVEF). No cardiac
symptoms
May 2018 Severe aortic valve stenosis and severe mitral valve
stenosis, preserved LVEF. No cardiac symptoms
June 2018 Surgical aortic and mitral valve replacement
September
2018
Patient deceased due to post-operative complications
with multiorgan failure





















..showed normal function as well as a normal LVEF in initial post-op-
erative transoesophageal echocardiography.
Histopathological examination of the removed aortic and mitral
valve showed severe calcification and the high presence of amyloid
by Congo-red staining and immunohistological staining for AA-
Amyloid (see Figure 5).
Post-operatively the patient suffered from severe systemic
inflammatory response syndrome (SIRS) with prolonged weaning, re-
current respiratory and abdominal septic shocks, cardiogenic shock
due to cardiac arrhythmias and multiple further complications.
Respiratory weaning was complicated by recurrent hospital-acquired
pneumonia with proof of Citrobacter koseri and Stenotrophomonas
Figure 1 Comparison of the transthoracical parasternal long-axis view in end-diastole from 2014 (left) and 2018 (right). Both exams show left
ventricular hypertrophy of interventricular septum = 19 mm (in 2014) and interventricular septum = 18 mm (in 2018). Aortic and mitral valve
morphology is normal in 2014 and shows massive thickening and reduced mobility in 2018. Notice the thickened mitral valve leaflets indicated by the
arrow. See also the additional Supplementary material online, Video S1. AVA, aortic valve area; IVS, interventricular septum; LVPW, left ventricular
posterior wall.
Figure 2 Comparison of apical five-chamber view with continuous wave Doppler across the aortic valve from 2014 (left) and 2018 (right, mean
pressure gradient: 30.56 mmHg). 2018 shows elevated peak systolic velocities.
































maltophilia in bronchoalveolar lavage. Weaning remained without
progress despite surgical tracheotomy and anti-infective treatment
(Tazobactam/Piperacillin/Ciprofloxacin). Furthermore, the patient
suffered from retractory Clostridium difficile enteritis, treated with van-
comycine/fidaxomicine. A rectoscopy in suspicion of gastrointestinal
bleeding (decrease in haemoglobin, peranal haemorrhage) revealed a
defect of distal rectum with tissue necrosis. Aetiology of the defect
remained unclear. An endosponge was inserted by laparoscopy and a
protective ileostomy was placed, local peritonitis was seen intraoper-
atively. Two days after bowel surgery, the patient’s condition wors-
ened with increasing demand of catecholamines in suspicion of
abdominal septic shock. Additionally, the patient showed repeated
ventricular arrhythmias with necessity of 10 min of reanimation and
multiple defibrillations. The patient died 3 months after surgical valve
replacement due to intractable multiorgan failure.
Discussion
We present a case with rapid progression of cardiac involvement in
systemic AA amyloidosis. Early diagnosis of CA was made at the stage
of already wide systemic involvement, including terminal chronic kid-
ney disease with necessity for dialysis and signs of cardiac remodel-
ling, but at that time no involvement of the valves or signs of cardiac
Figure 3 Comparison of apical four-chamber view with pulsed wave Doppler in 2014 and continuous wave Doppler in 2018 across the mitral
valve. Notice the normal E/A ratio in 2014 and the typical mitral valve stenosis pattern in 2018 (mitral valve mean pressure gradient = 13.92 mmHg).
Figure 4 Comparison of left ventricular global longitudinal strain visualized with automated function imaging showing the typical apical sparing
with the ‘cherry on the cake’ pattern already visible in 2014 (left) and intensified in 2018 (right). Outer circles correspond to the basal segments, the
centre corresponds to the apical segment. The longitudinal strain is visualized with red colouring for high longitudinal strain and blue colouring for
low longitudinal strain. Also, the longitudinal peak systolic strain apical to basal gradient [sum of apical strain values/(sum of midþ basal left ventricular
strain values)] is clearly pronounced in 2018.













































..decompensation. The patient developed severe aortic stenosis and
mitral valve stenosis in the period of 4 years, without presence of car-
diac symptoms. It must be considered that in this patient with
reduced mobility due to the underlying rheumatic disease and chron-
ic dialysis, awareness of cardiac symptoms such as dyspnoea and
reduced exercise capacity was low.
The mechanisms of aortic stenosis in AA amyloidosis are yet not
fully understood. On the one hand, in the present case, amyloid
was found in the histopathological examination of both valves.
On the other hand, patients on dialysis are more likely to develop
AS because of hyperphosphataemia, hypercalcaemia, and hyperpara-
thyroidism. In addition, increase in extracellular fluid volume,
anaemia, and increase in cardiac output due to vascular access lead to
increased flow velocity and turbulence across the aortic valve in
dialysis patients. These mechanisms can lead to fibrosis and aortic
valve calcification. It is likely that chronic kidney disease, mineral and
bone disorder influence onset and development of AS in dialysis
patients.7–10
The 2014 ESC Guidelines on diagnosis and management of hyper-
trophic cardiomyopathies recommend routine echocardiographic
controls every 12–24 months in clinical stable patients.11
The 2017 ESC Guidelines for the management of valvular heart dis-
ease6 recommend for patients with mild aortic stenosis to be reviewed
on a yearly basis and echocardiography performed every 2 years.
These recommendations were not followed, presumably due to a
lack of cardiac symptoms. The lack of specific cardiac symptoms
could be explained by the compensating mechanisms in a young heart
of a 40-year-old patient and the low awareness of these symptoms in
a patient with reduced mobility due to highly active rheumatic disease
and physical limitation due to chronic dialysis.
If the progression had been detected earlier, a better outcome
after cardiac surgery would have been probable due to a better over-
all situation and thus lower surgical risk.
Different mechanisms of the underlying disease should be consid-
ered in the fatal post-operative course:
Both Amyloidosis and kidney failure have been discussed in altering
vascular permeability.12–14 The underlying rheumatic disease was
treated with a monoclonal antibody biological drug therapy for
several years, which lead to immunosuppression. Still, the patient
post-operatively experienced severe SIRS, which lead to additional
capillary leakage. The patient suffered from recurrent respiratory
sepsis which lead to weaning failure and abdominal sepsis as potential
consequence from enhanced gastrointestinal capillary. Both the
patient’s acute on chronic kidney failure with need for continuous
dialysis leading to electrolyte deterioration and the accompanying
LVH in CA are risk factors for arrhythmias. The patient was defibril-
lated multiple times due to ventricular arrhythmias with cardiogenic
shock. Combined, these factors led to severe multiorgan failure and
patient’s death.
Conclusion
This severe progression of valve degeneration over a short period
shows the necessity of regular cardiological monitoring, including
echocardiography, for early detection of progression. Due to the
further increased risk in patients with restrictive and infiltrative cardi-
omyopathies and concomitant chronic dialysis we suggest echocar-
diographic controls in these patients every 6 months.
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Figure 5 Histology of the aortic valve biopsy specimen revealed amyloid deposits. Arrows indicate the amyloid positive area. Left: Congo red stain-












































































..Slide sets: A fully edited slide set detailing this case and suitable for local
presentation is available online as Supplementary data.
Consent: The author/s confirm that written consent for submission and
publication of this case report including image(s) and associated text has
been obtained from the patient in line with COPE guidance.
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